10709 related articles for article (PubMed ID: 15114060)
1. A novel approach for cancer immunotherapy: tumor cells with anchored superantigen SEA generate effective antitumor immunity.
Ma W; Yu H; Wang Q; Jin H; Solheim J; Labhasetwar V
J Clin Immunol; 2004 May; 24(3):294-301. PubMed ID: 15114060
[TBL] [Abstract][Full Text] [Related]
2. Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer.
Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; Yao H; Zhang W; Wang J; Cao X
J Mol Med (Berl); 2002 Sep; 80(9):585-94. PubMed ID: 12226740
[TBL] [Abstract][Full Text] [Related]
3. Immunization of mice with melanoma cells transfected to secrete the superantigen, staphylococcal enterotoxin A.
Shrayer DP; Kouttab N; Hearing VJ; Wanebo HJ
Cancer Immunol Immunother; 1998 Mar; 46(1):7-13. PubMed ID: 9520286
[TBL] [Abstract][Full Text] [Related]
4. Vaccination with IL-18 gene-modified, superantigen-coated tumor cells elicits potent antitumor immune response.
Wang Q; Yu H; Zhang L; Ju D; Pan J; Xia D; He L; Wang J; Cao X
J Cancer Res Clin Oncol; 2001 Dec; 127(12):718-26. PubMed ID: 11768611
[TBL] [Abstract][Full Text] [Related]
5. Potent antitumor effect elicited by superantigen-linked tumor cells transduced with heat shock protein 70 gene.
Huang C; Yu H; Wang Q; Ma W; Xia D; Yi P; Zhang L; Cao X
Cancer Sci; 2004 Feb; 95(2):160-7. PubMed ID: 14965367
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma.
Wang Q; Yu H; Ju DW; He L; Pan JP; Xia DJ; Zhang LH; Cao X
Gene Ther; 2001 Apr; 8(7):542-50. PubMed ID: 11319621
[TBL] [Abstract][Full Text] [Related]
7. [Preparation of mB7.1-GPI and SEA-TM dual-anchored tumor cell vaccine and its antitumor effect].
Yi PY; Yu H; Ma WX; Wang QQ; Huang CX; Li JZ
Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(18):1567-71. PubMed ID: 15500723
[TBL] [Abstract][Full Text] [Related]
8. Surface anchorage of superantigen SEA promotes induction of specific antitumor immune response by tumor-derived exosomes.
Xiu F; Cai Z; Yang Y; Wang X; Wang J; Cao X
J Mol Med (Berl); 2007 May; 85(5):511-21. PubMed ID: 17219095
[TBL] [Abstract][Full Text] [Related]
9. Tumor cells with B7.1 and transmembrane anchored staphylococcal enterotoxin A generate effective antitumor immunity.
Si SY; Hu PZ; Huang YY; Ye J; Huang Y; Li ZS; Ge W; Li X; Qu P; Zhang XM; Sui YF
Biochem Biophys Res Commun; 2006 Aug; 347(1):208-14. PubMed ID: 16814254
[TBL] [Abstract][Full Text] [Related]
10. Immune response during tumor therapy with antibody-superantigen fusion proteins.
Rosendahl A; Hansson J; Sundstedt A; Kalland T; Dohlsten M
Int J Cancer; 1996 Sep; 68(1):109-13. PubMed ID: 8895549
[TBL] [Abstract][Full Text] [Related]
11. Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex.
Asada H; Kishida T; Hirai H; Satoh E; Ohashi S; Takeuchi M; Kubo T; Kita M; Iwakura Y; Imanishi J; Mazda O
Mol Ther; 2002 May; 5(5 Pt 1):609-16. PubMed ID: 11991752
[TBL] [Abstract][Full Text] [Related]
12. Preparation of murine B7.1-glycosylphosphatidylinositol and transmembrane-anchored staphylococcal enterotoxin. A dual-anchored tumor cell vaccine and its antitumor effect.
Yi P; Yu H; Ma W; Wang Q; Minev BR
Cancer; 2005 Apr; 103(7):1519-28. PubMed ID: 15739200
[TBL] [Abstract][Full Text] [Related]
13. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
14. Murine B16 melanoma vaccination-induced tumor immunity: identification of specific immune cells and functions involved.
Wu TY; Fleischmann WR
J Interferon Cytokine Res; 2001 Dec; 21(12):1117-27. PubMed ID: 11798470
[TBL] [Abstract][Full Text] [Related]
15. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
[TBL] [Abstract][Full Text] [Related]
16. Vaccination with B16 melanoma cells expressing a secreted form of interleukin-1beta induces tumor growth inhibition and an enhanced immunity against the wild-type B16 tumor.
Björkdahl O; Dohlsten M; Sjögren HO
Cancer Gene Ther; 2000 Oct; 7(10):1365-74. PubMed ID: 11059695
[TBL] [Abstract][Full Text] [Related]
17. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
18. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS
Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815
[TBL] [Abstract][Full Text] [Related]
19. Long-term survival and complete cures of B16 melanoma-carrying animals after therapy with tumor-targeted IL-2 and SEA.
Rosendahl A; Kristensson K; Carlsson M; Skartved NJ; Riesbeck K; Søgaard M; Dohlsten M
Int J Cancer; 1999 Mar; 81(1):156-63. PubMed ID: 10077167
[TBL] [Abstract][Full Text] [Related]
20. A novel anticancer approach: SEA-anchored tumor cells expressing heat shock protein 70 onto the surface elicit strong anticancer efficacy.
Huang C; Yu H; Wang Q; Yang G; Ma W; Xia D; Chen X; Yi P; Shen F; Zheng H; Cao X
Immunol Lett; 2005 Oct; 101(1):71-80. PubMed ID: 15908014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
